Nanatinostat

DB15419InvestigationalSmall molecule

Nanatinostat is under investigation in clinical trial NCT00697879 (Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours).

Formula / weight: C₂₀H₁₉FN₆O₂ · 394.41 g/mol (avg)
Code names: CHR-3996 · VRx-3996

Resolves to

Compound

UNIIYTL7A418KQCAS1256448-47-1ChEMBLCHEMBL1801250

Structure

InChIKeyQRGHOAATPOLDPF-VQFNDLOPSA-NSMILESONC(=O)C1=CN=C(N=C1)N1C[C@H]2[C@@H](C1)[C@@H]2NCC1=NC2=CC=C(F)C=C2C=C1

Targets

Q92769HDAC2Q13547HDAC1O15379HDAC3

What you can answer from here — as of September 17, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

40Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nanatinostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account